Kytopen is an MIT startup developing their proprietary Flowfect technology for non-viral delivery of molecules into hard-to-transfect immune cells. The scalable Flowfect technology combines microfluidics and automation to make this process easier, faster, and cheaper than ever before. With our automated cell engineering platform we plan to enable new discoveries in biology that will lead to cost effective cell and gene therapies.